Targeting Mitochondrial Dysfunction

For our lead product, Imeglimin, a New Drug Application was submitted in Japan by Sumitomo Dainippon Pharma in July 2020. Imeglimin has successfully completed Phase 2 development in the U.S. and EU. PXL770 and PXL065 are in mid-stage development for NASH. We are also evaluating our AMPK activation and TZD platforms for other chronic and rare metabolic diseases.

View Our Candidates
Targeting Mitochondrial Dysfunction

Innovative Pipeline of First-In-Class Products

Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes and NASH.

View Pipeline
Innovative Pipeline of First-In-Class Products

Backed by Strong Leadership

Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.

Meet Our Team
Backed by Strong Leadership

Latest News

Poxel Announces Participation at Upcoming Scientific and Investor Conferences

LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and…

Read this Press Release: Poxel Announces Participation at Upcoming Scientific and Investor Conferences

Poxel Reports Financial Results for First Half 2020 and Provides a Corporate Update

Strengthened financial position during H1 2020 with drawdown of IPF loan of EUR 10 million and a capital raise of EUR 17.7 million Imeglimin New Drug Application in Japan (J-NDA) was submitted for the treatment of…

Read this Press Release: Poxel Reports Financial Results for First Half 2020 and Provides a Corporate Update
Click here to show the previous slide Click here to show the next slide